The Medicines Co. Sets The (Commercial) Stage For New Launches
This article was originally published in The Pink Sheet Daily
Executive Summary
CEO Clive Meanwell detailed plans to deploy a 400-person commercial group in the U.S. to target 1,100 leading hospitals in the U.S.
You may also be interested in...
The Medicines Co. Names Mark Timney As CEO In A Shakeup
CEO Clive Meanwell helped to shape the company over his nearly 22 years at the helm, including when it marketed a portfolio of hospital-based drugs. Now the company is solely focused on shepherding the PCSK9 inhibitor inclisiran to the finish line.
Finance Watch: Summer Slowdown Begins Ahead Of BIO, But Two IPOs Launched
Athenex and Immuron launched IPOs in the US, but June has otherwise been a pretty quiet month for new biopharma financings – so far. The largest VC round so far this month is Checkmate's $27m Series B and the biggest public offering was conducted by CTI BioPharma, raising $45m.
Angiomax Generic From Hospira Might Launch At-Risk Launch In 2015
District Court upholds validity of TMC’s process patents for its anticoagulant but finds Hospira does not infringe them.